These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 26631606)

  • 1. Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population.
    Vos JR; Mourits MJ; Teixeira N; Jansen L; Oosterwijk JC; de Bock GH
    Gynecol Oncol; 2016 Feb; 140(2):289-94. PubMed ID: 26631606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A targeted analysis identifies a high frequency of BRCA1 and BRCA2 mutation carriers in women with ovarian cancer from a founder population.
    Belanger MH; Dolman L; Arcand SL; Shen Z; Chong G; Mes-Masson AM; Provencher D; Tonin PN
    J Ovarian Res; 2015 Mar; 8():1. PubMed ID: 25884701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ten-year survival after epithelial ovarian cancer is not associated with BRCA mutation status.
    Kotsopoulos J; Rosen B; Fan I; Moody J; McLaughlin JR; Risch H; May T; Sun P; Narod SA
    Gynecol Oncol; 2016 Jan; 140(1):42-7. PubMed ID: 26556769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Very high uptake of risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers: A single-center experience.
    Harmsen MG; Arts-de Jong M; Horstik K; Manders P; Massuger LFAG; Hermens RPMG; Hoogerbrugge N; Woldringh GH; de Hullu JA
    Gynecol Oncol; 2016 Oct; 143(1):113-119. PubMed ID: 27430397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. When to Consider Risk-Reducing Mastectomy in BRCA1/BRCA2 Mutation Carriers with Advanced Stage Ovarian Cancer: a Case Study Illustrating the Genetic Counseling Challenges.
    Speight B; Tischkowitz M
    J Genet Couns; 2017 Dec; 26(6):1173-1178. PubMed ID: 28780755
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of pregnancy as a risk factor for breast cancer in BRCA1/BRCA2 mutation carriers.
    Cullinane CA; Lubinski J; Neuhausen SL; Ghadirian P; Lynch HT; Isaacs C; Weber B; Moller P; Offit K; Kim-Sing C; Friedman E; Randall S; Pasini B; Ainsworth P; Gershoni-Baruch R; Foulkes WD; Klijn J; Tung N; Rennert G; Olopade O; Couch F; Wagner T; Olsson H; Sun P; Weitzel JN; Narod SA
    Int J Cancer; 2005 Dec; 117(6):988-91. PubMed ID: 15986445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T; Permuth-Wey J; Betts JA; Krischer JP; Fiorica J; Arango H; LaPolla J; Hoffman M; Martino MA; Wakeley K; Wilbanks G; Nicosia S; Cantor A; Sutphen R
    Cancer; 2005 Dec; 104(12):2807-16. PubMed ID: 16284991
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
    J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study.
    Nyberg T; Frost D; Barrowdale D; Evans DG; Bancroft E; Adlard J; Ahmed M; Barwell J; Brady AF; Brewer C; Cook J; Davidson R; Donaldson A; Eason J; Gregory H; Henderson A; Izatt L; Kennedy MJ; Miller C; Morrison PJ; Murray A; Ong KR; Porteous M; Pottinger C; Rogers MT; Side L; Snape K; Walker L; Tischkowitz M; Eeles R; Easton DF; Antoniou AC
    Eur Urol; 2020 Jan; 77(1):24-35. PubMed ID: 31495749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fertility treatments and invasive epithelial ovarian cancer risk in Jewish Israeli BRCA1 or BRCA2 mutation carriers.
    Perri T; Lifshitz D; Sadetzki S; Oberman B; Meirow D; Ben-Baruch G; Friedman E; Korach J
    Fertil Steril; 2015 May; 103(5):1305-12. PubMed ID: 25792249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations.
    Brohet RM; Velthuizen ME; Hogervorst FB; Meijers-Heijboer HE; Seynaeve C; Collée MJ; Verhoef S; Ausems MG; Hoogerbrugge N; van Asperen CJ; Gómez García E; Menko F; Oosterwijk JC; Devilee P; van't Veer LJ; van Leeuwen FE; Easton DF; Rookus MA; Antoniou AC;
    J Med Genet; 2014 Feb; 51(2):98-107. PubMed ID: 24285858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The 3020insC NOD2 gene mutation in patients with ovarian cancer.
    Magnowski P; Medrek K; Magnowska M; Stawicka M; Kedzia H; Górski B; Lubiński J; Spaczyński M
    Ginekol Pol; 2008 Aug; 79(8):544-9. PubMed ID: 18819462
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Germline BRCA1/2 mutation testing is indicated in every patient with epithelial ovarian cancer: A systematic review.
    Arts-de Jong M; de Bock GH; van Asperen CJ; Mourits MJ; de Hullu JA; Kets CM
    Eur J Cancer; 2016 Jul; 61():137-45. PubMed ID: 27209246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers.
    Antoniou AC; Shenton A; Maher ER; Watson E; Woodward E; Lalloo F; Easton DF; Evans DG
    Breast Cancer Res; 2006; 8(6):R72. PubMed ID: 17187672
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic anticipation in BRCA1/BRCA2 families after controlling for ascertainment bias and cohort effect.
    Guindalini RS; Song A; Fackenthal JD; Olopade OI; Huo D
    Cancer; 2016 Jun; 122(12):1913-20. PubMed ID: 26992017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.